Citius Pharmaceuticals (NASDAQ:CTXR) Issues Earnings Results, Misses Estimates By $0.05 EPS

Citius Pharmaceuticals (NASDAQ:CTXR) released its quarterly earnings results on Friday. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by ($0.05), Zacks reports.

Citius Pharmaceuticals Trading Down 0.4 %

Shares of CTXR stock opened at $2.69 on Friday. The business’s 50 day moving average is $3.15 and its two-hundred day moving average is $8.60. Citius Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $26.75. The company has a market capitalization of $23.12 million, a P/E ratio of -0.45 and a beta of 1.28.

Analyst Ratings Changes

CTXR has been the topic of a number of research reports. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

About Citius Pharmaceuticals

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.